最大肿瘤直径与局限期霍奇金淋巴瘤复发风险相关:一项国际研究
该国际研究在H10试验中外部验证RAPID试验发现,即最大肿瘤直径(MTD)与局限期霍奇金淋巴瘤(LS-HL)患者达到PET阴性后的复发风险相关。H10中MTD与无事件生存强相关(HR 1.22,95%CI 1.07-1.38,P=0.003),与RAPID相似(HR 1.19,95%CI 1.02-1.39,P=0.02),合并HR 1.21(95%CI 1.09-1.33,P<0.001),每厘米MTD估计风险增加21%。单纯ABVD与ABVD联合放疗的效果相似,无差异效应(交互作用P=0.97)。
要点
- 在达到PET阴性的局限期霍奇金淋巴瘤患者中,最大肿瘤直径与复发风险强相关。
- H10试验中MTD的HR为1.22(95%CI 1.07-1.38,P=0.003),RAPID试验中为1.19(95%CI 1.02-1.39,P=0.02)。
- 合并HR为1.21(95%CI 1.09-1.33,P<0.001),估计每厘米MTD风险增加21%。
核心结论
- 该国际验证研究证实,在达到PET阴性的局限期霍奇金淋巴瘤患者中,最大肿瘤直径与复发风险强相关,并有助于围绕风险适配的放疗应用进行决策。
研究设计与样本
- 国际验证研究,纳入H10试验中I/IIA期、无纵隔巨块、经ABVD达到PET阴性的霍奇金淋巴瘤患者,并对比RAPID试验数据。
- RAPID试验中患者接受3周期ABVD联合放疗(n=208)或3周期ABVD alone(n=211)。
- H10试验中患者接受3至4周期ABVD联合放疗(n=556)或4至6周期ABVD alone(n=303)。
主要发现
- H10试验中MTD与无事件生存(复发或HL相关死亡)强相关,HR为1.22(95%CI 1.07-1.38,P=0.003)。
- RAPID试验中MTD与无事件生存的关联相似,HR为1.19(95%CI 1.02-1.39,P=0.02)。
- 合并估计每厘米MTD风险增加21%(HRpooled 1.21,95%CI 1.09-1.33,P<0.001)。
- 单纯ABVD与ABVD联合放疗患者的效应大小相似,无差异效应(交互作用P=0.97)。
- 治疗方式和MTD为独立风险因素;MTD较高且接受单纯化疗的患者复发风险最大。
临床怎么用
- 原文结论指出,该研究结果有助于围绕风险适配的放疗应用进行决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor bulk is an established prognostic factor in Hodgkin lymphoma (HL), but most patients with limited-stage (LS) HL do not have "bulk" by standard definitions. In the RAPID trial, maximum tumor diameter (MTD) was associated with relapse risk in LS-HL patients achieving positron emission tomography negativity (PET-) after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). We aimed to externally validate these findings in the H10 trial. Stage I/IIA HL patients, without mediastinal bulk, who achieved PET- with ABVD were included. Patients received 3 ABVD plus radiotherapy (n = 208) or 3 ABVD alone (n = 211) in RAPID, and 3 to 4 ABVD plus radiotherapy (n = 556) or 4 to 6 ABVD alone (n = 303) in H10. MTD was strongly associated with event-free survival (relapse or HL-related death) in H10 (hazard ratio [HR], 1.22; 95% confidence interval [CI], 1.07-1.38; P = .003), a similar effect to that seen in RAPID (HR, 1.19; 95% CI, 1.02-1.39; P = .02), giving an estimated 21% risk increase per centimeter MTD (HRpooled, 1.21; 95% CI, 1.09-1.33; P < .001). Effect sizes were similar for patients treated with ABVD alone and ABVD plus radiotherapy, with no differential effect (pinteraction = 0.97). Treatment modality and MTD were independent risk factors; patients with higher MTD receiving chemotherapy alone had the greatest relapse risk. This international validation study confirms MTD is strongly associated with relapse risk in patients with LS-HL achieving PET- and informs decision-making around risk-adapted application of radiotherapy. The trials were registered at www.clinicaltrials.gov as #NCT00943423 and #NCT00433433.
引用
- Phillips EH, Counsell N, Illidge T, et al. Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study. Blood Adv. 2025. PMID: 39774828. doi:10.1182/bloodadvances.2024015140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。